Lantern Phar­ma charts course for IPO with AI plat­form that shines light on failed can­cer drugs

Ar­ti­fi­cial in­tel­li­gence — the cure-all for the pesky process of mak­ing a ther­a­peu­tic, in­clud­ing da­ta min­ing, drug dis­cov­ery, op­ti­mal drug de­liv­ery and ad­dress­able pa­tient pop­u­la­tion — is be­ing em­ployed by yet an­oth­er biotech: Lantern Phar­ma.

The com­pa­ny, which us­es its AI plat­form to iden­ti­fy pa­tients that could ben­e­fit from its tar­get­ed on­col­o­gy ther­a­pies, on Thurs­day un­veiled plans to make its pub­lic de­but in an up to $29 mil­lion IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.